

1 **Measuring what matters: context-specific indicators for assessing immunisation performance in**
2 **Pacific Island Countries and Areas**

3

4 Authors: *Cyra Patel¹, Ginny M Sargent¹, Adeline Tinessia², Helen Mayfield³, Dan Chateau¹, Akeem
5 Ali⁴, Ilisapeci Tuibeqa⁵, *Meru Sheel^{1,2,6}

6

7 1 National Centre for Epidemiology and Population Health, Australian National University, Canberra
8 ACT 2601, Australia

9 2 Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney,
10 Camperdown NSW 2006, Australia

11 3 UQ Centre for Clinical Research, The University of Queensland, Brisbane QLD 4029, Australia

12 4 World Health Organization, Seoul, Republic of Korea

13 5 Department of Paediatrics, Colonial War Memorial Hospital, Suva, Fiji

14 6 Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, The University of Sydney,
15 Westmead NSW 2145, Australia

16

17 *Corresponding authors

18 Cyra.Patel@anu.edu.au

19 Meru.Sheel@sydney.edu.au

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **Abstract**

21 Increasing countries' access to data can improve immunisation coverage through evidence-based
22 decision-making. However, data collection and reporting is resource-intensive, so needs to be
23 pragmatic, especially in low-and-middle-income countries. We aimed to identify which indicators are
24 most important for measuring, and improving, national immunisation performance in Pacific Island
25 Countries (PICs). We conducted an expert elicitation study, asking 13 experts involved in delivering
26 immunisation programs, decision-makers, health information specialists, and global development
27 partners across PICs to rate 41 indicators based on their knowledge of the feasibility and relevance
28 of each indicator. We also asked experts their preferences for indicators to be retained or removed
29 from a list of indicators for PICs. Experts participated in two rating rounds, with a discussion on the
30 reasons for ratings before the second round. We calculated mean scores for feasibility and
31 relevance, and ranked indicators based on experts' preferences and mean scores. We used
32 framework analysis to identify reasons for selecting indicators. Experts agreed that certain indicators
33 were essential to measure (e.g. data use in program planning and measles vaccination coverage),
34 but preferences varied for most indicators. Preferences to include indicators in a set of indicators for
35 PICs moderately correlated with scores for relevance ($r=0.68$) and feasibility ($r=0.56$). In discussions,
36 experts highlighted usefulness for decision-making and ease of data collection, reporting and
37 interpretation as the main reasons driving indicator selection. Country-specific factors such as health
38 system factors, roles and influence of various immunisation actors, and macro-level factors (namely
39 population size, distribution and mobility) affected relevance and feasibility, leading us to conclude
40 that a single set of indicators for all PICs is inappropriate. Rather than having a strict set of indicators
41 that all countries must measure and report against, performance indicators should be flexible,
42 country-specific, and selected in consultation with stakeholders who collect and use the data.

43

44 Key words: Immunisation, Monitoring & evaluation, Vaccination, Global health, Indicators, Pacific

45 Island Countries and Areas

46 **Introduction**

47 The Immunization Agenda 2030, the global strategy guiding progress on immunisation for the
48 decade 2021–2030 endorsed by WHO member states, emphasises having “high-quality, fit-for-
49 purpose data” to be the basis of decision-making to drive improvements in immunisation
50 performance.¹ Greater access to data and evidence-based decision-making is considered critical to
51 improve policies and practices, leading to better public health outcomes including higher and more
52 equitable immunisation coverage.²

53

54 However, the push for data-driven decision-making has led to an expanding volume of indicators for
55 which data are collected and reported, with our recent review identifying over 600 distinct
56 indicators being used to measure national immunisation system performance.³ This volume of
57 performance indicators can have unintended consequences if the resources dedicated to collecting
58 data lead to resources being diverted away from programs.^{4,5} Furthermore, there is little evidence
59 that these data are used to inform decision-making about immunisation programs, particularly in
60 low-and-middle-income countries.⁶ Having data for a multitude of indicators may not be useful to
61 national-level decision-makers and program managers if the data do not inform current policy
62 considerations, program implementation and resource allocation.^{2,6,7} To be useful in decision-
63 making, indicators must be aligned with the priorities of actors and the context,⁸ but existing
64 monitoring and evaluation tools are rarely contextualised to a specific country or setting, raising the
65 question of whether the top-down approach for monitoring and evaluation at a global level is
66 appropriate.⁹

67

68 With this in mind, we examined what is most useful to measure, and what is less useful or irrelevant,
69 to assess immunisation performance in a distinct geographical region. Pacific Island Countries and
70 Areas (PICs) comprise 21 small island countries and areas (excluding Papua New Guinea), with 3.2
71 million people living in an area disbursed over approximately 30% of the Earth’s surface.¹⁰ Many PICs

72 face common challenges such as small populations (no country’s population exceeds 1 million
73 people), a highly constrained health workforce and underdeveloped information technology
74 infrastructure.^{11–14} Yet, PICs are heterogeneous, with varying population sizes (from less than 2,000
75 people in Niue to approximately 900,000 in Fiji), geographic size and population dispersion (e.g.
76 concentrated in one or few islands such as Niue and Samoa, while others are dispersed over as many
77 as 147 islands such as the Solomon Islands and French Polynesia).¹⁰ Local health system capacity,
78 political and governance structures (especially as some are independent while others are affiliated
79 with other high-income countries namely the United States, France, New Zealand and Britain), and
80 resources also vary.¹⁴ Most PICs used paper-based registries and tally sheets to report immunisation
81 data prior to the COVID-19 pandemic, although some (particularly US-Affiliated Pacific Islands) had
82 electronic immunisation registers.¹⁵ During the COVID-19, some PICs introduced new digital systems
83 to collect and aggregate immunisation data pandemic, and are at varying stages of
84 implementation.^{16,17} While coverage of childhood immunisation was relatively high across PICs prior
85 to the COVID-19 pandemic (average of 91.4% for the third dose of diphtheria-tetanus-pertussis
86 (DTP) vaccine [DTP3] and 88.1% for the first dose of measles vaccine [MCV1] in 2019), noting
87 variation across the region, many countries experienced pandemic-related disruptions to
88 immunisation programs (coverage of DTP3 fell to 86.8% and MCV1 to 75.6% in 2021).^{18,19} In this
89 study, we aimed to identify which indicators are critical to measure immunisation performance in
90 PICs and the reasons for selecting these indicators.

91

92 **Materials and methods**

93 *Definitions*

94 There are multiple and variable definitions for what constitutes data use, with terms often discussed
95 interchangeably. For the purposes of this study, we used the PRISM-Act framework, and classified
96 activities related to collecting, organising, analysing, synthesising and disseminating (including
97 reporting) data as tasks that precede data use, collectively referred to as “data collection and

98 reporting”.²⁰ “Data use” constituted actions where the data produced is reviewed, discussed and
99 considered in planning, strategizing and decision-making, including to evaluate performance. To
100 avoid confusion, we referred to data that is ready for use as “insights”. Additionally in this paper,
101 feasibility refers to the ease of completing the processes from data collection through to reporting,
102 while relevance to decision-making refers to the usefulness of insights for policy and planning
103 considerations.

104

105 *Study design*

106 This study utilised a semi-structured expert-elicitation approach to consult with key stakeholders
107 and determine priorities for immunisation indicators in PICs. Expert elicitation is an approach to
108 elicit the knowledge of experts that aims to increase accuracy and transparency in making
109 judgements while reducing biases and quantifying uncertainty in their judgements compared with
110 other methods of eliciting expert judgement.^{21,22} We adapted the steps detailed in the IDEA
111 (Investigate, Discuss, Estimate, Aggregate) structured protocol for expert elicitation.²¹ We adopted
112 good practice steps identified in the elicitation literature, including: preparing the expert for the
113 elicitation, having a formal framework for the elicitation session, obtaining feedback from the expert
114 on the results and offering the possibility of adjusting their response.²³

115

116 *Recruitment and study population*

117 We invited stakeholders involved in delivering immunisation programs across the 21 PICs to
118 participate in this study, including immunisation program managers, government decision-makers
119 from ministries of health, health information specialists working with immunisation data, global
120 development partner representatives at the regional or national levels, and international experts,
121 advisors and researchers implementing immunisation programs or information systems in PICs.
122 Experts were recruited between 21/11/2022 and 07/04/2023.

123

124 We purposively identified eligible individuals through publicly available information, such as lists of
125 meeting attendees at regional immunisation meetings, as well as those known to the research team
126 and snowballing. We contacted participants via email with a single follow-up email. We aimed to
127 recruit 15 to 20 experts to allow for a 25% attrition rate.

128

129 *Development of elicitation instrument*

130 The elicitation instrument comprised a list of indicators that experts were asked to rate based on
131 specified criteria (see Appendix 1). The list of indicators was identified from a comprehensive review
132 of 631 distinct indicators measuring the performance of immunisation systems.³ To make the list
133 manageable, we only included indicators measuring outcomes of immunisation systems (focusing on
134 full or incomplete vaccination coverage and equity of coverage, n=35) and the performance of the
135 systems through which those data were obtained (n=92). We excluded indicators that were
136 duplicated, pertained to a specific program or context, lacked clarity in their definition and
137 calculation, and from monitoring and evaluation resources published more than 10 years prior or
138 those preceded by another resource (n=92). We additionally reviewed indicators categorised as
139 measuring other components of immunisation systems but crossed over with information systems,
140 namely regulation and pharmacovigilance (n=3), governance and program planning (n=2), and
141 vaccine logistics (n=1).

142

143 The 41 included indicators were categorised into five sections (see Appendix 2):

- 144 1. Indicators measuring immunisation coverage (n=12)
- 145 2. Indicators measuring insights use (n=4)
- 146 3. Indicators measuring data quality (n=9)
- 147 4. Indicators measuring the data systems and processes for collecting and reporting
148 immunisation data (n=10)
- 149 5. Indicators assessing vaccine-preventable disease (VPD) surveillance system (n=6)

150

151 Experts were asked to rate each indicator based on whether data were feasible to collect and report,
152 and how relevant the indicator was to decision-making. We also asked experts to select their
153 preferred indicators within each category, and asked them to select indicators to “keep” or
154 “remove” from a list of indicators monitoring national immunisation performance. The rating criteria
155 are described in Table 1.

Table 1: Definitions of rating criteria used to elicit experts' opinions on immunisation performance monitoring indicators

| Rating criteria | Definition | Assessment method | Variable type | Analysis method |
|---|---|---|--|---|
| Feasibility | The ease of collecting and reporting high quality data for the indicator | For each indicator, experts were asked whether data for the indicator was: <ol style="list-style-type: none"> 1) Collected 2) Reported 3) Of high quality Experts could select from the following options: <ul style="list-style-type: none"> • Yes • No • Unsure • Not applicable | Collected as categorical; converted to numeric during analysis | For each indicator, proportions calculated for experts who stated “yes” to 1) data is collected, 2) data is reported, and 3) data is of high quality. For each individual expert, a feasibility score was calculated for each indicator by assigning a score of “1” for each “yes” response to the three items and summing them for a score out of 3. This was scaled to a score out of 10 (i.e. divide by 3, multiply by 10). A mean feasibility score for each indicator was then calculated by averaging all experts' feasibility scores for the indicator. |
| Relevance (and confidence in relevance) | Relevance: The importance of the indicator in informing decision-making about immunisation Confidence: The level of certainty in the score provided for relevance, i.e. how sure the expert felt about their relevance score | For each indicator, experts were asked to provide a numeric value between 0 and 10 (0=lowest, 10=highest) for both relevance and their level of confidence in that relevance score | Numeric | Crude mean relevance score for each indicator was calculated by averaging the numeric scores by each expert. Weighted relevance score for each indicator was calculated by averaging experts' adjusted relevance scores. Adjusted relevance scores were calculated for each expert by weighting their relevance score using their confidence score. |
| Preference | Indicators that experts preferred to “keep” or “remove” in a shorter list of indicators measuring national immunisation performance in PICs | Experts were asked to select a specified number of indicators (i.e. top 25% and bottom 25%) to “keep” and “remove” within each of the five categories | Collected as categorical; converted to numeric during analysis | A preference score was calculated for each indicator, based on the number who selected “keep” minus the number who selected “remove”. |

158 The elicitation instrument was iteratively developed and refined amongst the research team, and
159 then revised following testing with three volunteers and piloting with three experts. Following minor
160 revisions, the elicitation instrument was finalised.

161

162 *Expert elicitation process*

163 Figure 1 summarises the expert elicitation process that we followed. We conducted the elicitation
164 over two rounds. In the first round (December 2022 to April 2023), the first author (CP) met
165 individually with experts via web conferencing (Zoom) to discuss the purpose of the study and the
166 criteria for rating indicators. Experts then independently completed the elicitation instrument
167 electronically via a Qualtrics survey (see Appendix 1). Their responses were summarised in feedback
168 reports that were sent to experts, showing group means compared with the expert's individual
169 responses.

170

171 ***Insert Figure 1: Flowchart showing the process of expert elicitation followed in this study***

172

173 In Round 2, experts participated in a qualitative discussion (via web conferencing using Zoom) to
174 review results and explore the reasons for differences in the values given by each expert compared
175 to the group. Discussions were completed in small groups of 2–3 experts or individually, based on
176 experts' availability and preferences (individual results were anonymised). Discussions were
177 structured to review indicator rankings within each of the five categories, and then the overall
178 highest ranked indicators. Open-ended questions were framed to understand the reasons behind
179 experts' ratings, the context they worked in, their professional experiences and the assumptions
180 being made. Specific questions included why they thought an indicator was ranked high (or low), and
181 how they might use an indicator in their context. Experts were also asked about their preferences
182 for characteristics of sets of indicators, specifically how many indicators they think a national set of
183 immunisation performance indicators should be limited to and why. Every expert was then sent a

184 brief summary of all discussions, and asked to rate all 41 indicators a second time (June to August
185 2023).

186

187 *Ethical approval*

188 The Australian National University Human Research Ethics Committee reviewed and approved the
189 ethical conduct of this study (protocol 2022/368) and amendments to data collection tools.

190 Informed consent was obtained verbally during the first meeting. Experts were asked to confirm
191 their consent to participate at the time they completed the elicitation instrument online.

192

193 *Analysis*

194 We included results for experts who completed both rounds of the elicitation only. We analysed
195 indicator ratings descriptively, calculating the proportion of experts who stated that data could be
196 collected, reported and were high quality for each indicator. We generated a feasibility score for
197 each expert's indicator rating, by assigning a score of 1 for each "yes" response to the three
198 feasibility items and summing these for a score out of 3, and then scaling this to a total out of 10.

199 We generated mean relevance scores for each indicator by weighting the crude mean relevance
200 scores assigned by experts with their confidence scores. We then generated a composite feasibility-
201 relevance score for each indicator by averaging the mean feasibility and relevance scores.

202

203 We calculated a "preference score" for each indicator by subtracting the number of experts who
204 said they would "remove" the indicator from those who said they would "keep" that indicator. We
205 then used the preference scores and composite feasibility-relevance scores to rank the 41 indicators.

206 Table 1 and Appendix 3 provides details on how these scores and rankings were calculated.

207

208 We additionally examined indicator rankings by different expert groups, namely by gender, expertise
209 (public health and immunisation versus digital health) and geographical scope of work (one country

210 versus more than one country), and describe findings narratively. We examined the relationships
211 between the different rating criteria using graphs and calculated correlation coefficients between
212 the rating criteria.

213

214 To understand the reasons driving preferences for indicators, we analysed the discussions with
215 experts from Round 2 using framework analysis, following the steps outlined by Ward et al.²⁴ We
216 used an iterative process and inductive approach to identify themes. One author (CP) reviewed the
217 interview transcripts and summarised salient discussion points, which were used to identify an initial
218 set of themes, organised into overarching concepts (constructs) which were discussed and refined
219 by all authors. Two authors (CP and AT) reviewed three transcripts (covering 7/13 participants) in
220 detail to test how well the themes fit. The themes were revised following discussion with all authors.
221 CP and AT then independently coded three interview transcripts (covering 5/13 participants) and
222 discussed discrepancies in coding. Interviews were coded using NVivo 12. After further discussion
223 with authors, the themes were refined and finalised. A single author (CP) then coded remaining
224 interviews based on the agreed themes and definitions (see Appendix 4), and extracted data into a
225 framework examining themes by each expert and their context. Findings are summarised
226 narratively.

227

228 **Results**

229 Twenty-two experts agreed to participate in the study – 16 (72.7%) completed the first round of
230 which 13 (81.3%) completed the second round and were included in the final analysis. Table 2 shows
231 the characteristics of included experts. Seven experts worked in multiple Pacific Island countries or
232 across the region, while six worked in a single country. Specific countries represented included Fiji,
233 French Polynesia, Kiribati, Niue, Samoa, Solomon Islands and Vanuatu. Ten were experts in
234 immunisation and public health, and three were experts in health information systems. Most (11/13,
235 85%) had worked in Pacific Island countries for more than 2 years.

237 **Table 2: Characteristics of included study participants (n=13)**

| Characteristic | n | % |
|---|----------|----------|
| Gender of respondent | | |
| Male | 6 | 46.2 |
| Female | 7 | 53.9 |
| Age of respondent | | |
| 18-29 years | 2 | 15.4 |
| 30-39 years | 4 | 30.8 |
| 40-49 years | 4 | 30.8 |
| 50-59 years | 2 | 15.4 |
| 60 years or older | 1 | 7.7 |
| Time working in PICs | | |
| <1 year | 1 | 7.7 |
| 1–<2 years | 1 | 7.7 |
| 2–<5 years | 4 | 30.8 |
| 5–<9 years | 3 | 23.1 |
| ≥10 years | 4 | 30.8 |
| Type of expert | | |
| Ministry/department of health employee | 5 | 38.5 |
| Global development partner representative | 2 | 15.4 |
| Consultant or researcher | 6 | 46.2 |
| Subject matter focus area | | |
| Immunisation and public health | 10 | 76.9 |
| Digital health | 3 | 23.1 |
| Geographical area of focus | | |
| Global or regional | 7 | 53.8 |
| National | 6 | 46.2 |
| Time working in current role | | |
| <1 year | 0 | 0.0 |
| 1–<2 years | 6 | 46.2 |
| 2–<5 years | 2 | 15.4 |
| 5–<9 years | 4 | 30.8 |
| ≥10 years | 1 | 7.7 |

238

239

240

241 *Results of indicator ratings and rankings*

242 Table 3 shows the summary of preference, feasibility and relevance scores for each indicator.

243 Feasibility scores ranged between 0.77 to 7.18 (details in Appendices 5 and 6), with only 9 indicators
244 receiving a score above 5. Mean weighted relevance scores varied between 4.97 and 9.05, noting
245 that most indicators (33/41, 80.5%) received mean crude and weighted scores between 7 and 9 (see
246 Appendix 5). Preference scores were moderately correlated with composite feasibility-relevance
247 ($r=0.68$), weighted relevance ($r=0.68$) and feasibility ($r=0.56$) scores (Figure 2). The two attributes
248 examined in this study, feasibility and relevance to decision-making, were moderately correlated
249 ($r=0.52$, Figure 3).

250

251 **<Insert Figures 2 and 3 here>**

252

253 **Figure 2: Plots comparing mean scores by rating criteria for all indicators**

254 *Caption: The graphs show how preference scores varied by the rating criteria used in this study (i.e.*
255 *feasibility, relevance, and a composite feasibility-relevance score) for each indicator. They show*
256 *moderate correlations of preference scores with each of the rating criteria.*

257 *Notes:*

- 258 • *Top third: Highest ranked indicators (top one-third, indicators that ranked 1–14)*
- 259 • *Middle third: Middle-ranked indicators (middle one-third, indicators that ranked 15–29)*
- 260 • *Bottom third: Lowest-ranked indicators (lowest one-third, indicators that ranked 30–41)*
- 261 • *r = correlation coefficient between rating attributes*

262 **Insert Figures 2A–2D**

263 A. *Preference scores vs composite feasibility-relevance scores*

264 B. *Preference score vs relevance score (weighted)*

265 C. *Preference score vs feasibility score*

266 D. *Crude relevance vs confidence*

267

268 **Figure 3: Plot showing mean weighted relevance scores and mean feasibility scores for all**
269 **indicators**

270 *Caption: The graphs show how scores for the two rating criteria used in this study, i.e. feasibility and*
271 *relevance (weighted by confidence scores), varied for each indicator. The graphs show a moderate*
272 *correlation between mean feasibility and mean weighted preference scores.*

273 *Notes:*

- 274 • *Top third: Highest ranked indicators (top one-third, indicators that ranked 1–14)*
- 275 • *Middle third: Middle-ranked indicators (middle one-third, indicators that ranked 15–29)*
- 276 • *Bottom third: Lowest-ranked indicators (lowest one-third, indicators that ranked 30–41)*

277 *r = correlation coefficient between rating attributes*

278

Table 3: Indicators listed by their rank based on scores provided by experts for preference, mean feasibility and mean relevance-to-decision-making

| Rank | Indicator | Category | Preference score | Mean feasibility-relevance score | Mean feasibility score | Mean weighted relevance score |
|------|--|----------------------------|------------------|----------------------------------|------------------------|-------------------------------|
| 1 | Country uses quality data on under-vaccinated to inform plans at community, subnational and national levels | Use of insights | 10 | 6.96 | 4.87 | 9.05 |
| 2 | Proportion of live births registered | Data quality | 6 | 8.05 | 7.18 | 8.92 |
| 3 | Number of districts with measles (MCV1) coverage in each range: <50%, 50-79%, 80-89%, 90-94, ≥95% | Immunisation coverage | 6 | 7.35 | 6.41 | 8.29 |
| 4 | Number of districts with measles (MCV2) coverage in each range: <50%, 50-79%, 80-89%, 90-94, ≥95% | Immunisation coverage | 6 | 7.18 | 5.38 | 8.98 |
| 5 | Is there a national system to monitor adverse events following immunisation (AEFIs)? | Data systems and processes | 6 | 6.79 | 4.62 | 8.97 |
| 6 | Availability of sustainable and effective immunisation information system integrated within a robust national health information system | Data systems and processes | 6 | 6.43 | 3.85 | 9.01 |
| 7 | Number of zero dose children, i.e. those that lack access to or are never reached by routine immunisation services (operationally measured as those who lack first dose of a DTP-containing vaccine) | Immunisation coverage | 5 | 7.31 | 6.15 | 8.47 |
| 8 | Proportion of polio, measles, meningococcal disease, yellow fever, cholera, and Ebola outbreaks with timely detection and response | VPD surveillance systems | 4 | 6.34 | 3.85 | 8.84 |
| 9 | Proportion of facility-level routine immunisation microplans with updated catchment area maps and strategy to reach them | Data quality | 4 | 4.69 | 2.05 | 7.34 |
| 10 | Linkage of home-based records with civil birth registration through immunisation services | Data systems and processes | 3 | 5.01 | 2.56 | 7.45 |
| 11 | Dropout rates between first dose (DTP1) and third dose (DTP3) of DTP-containing vaccine | Immunisation coverage | 2 | 7.13 | 5.90 | 8.36 |
| 12 | Proportion of districts with complete and timely reporting from all health facilities | Data quality | 2 | 6.93 | 6.15 | 7.70 |
| 13 | Non-polio acute flaccid paralysis (AFP) rate (target >1/100,000 among <15 years population) in a 12-month period | VPD surveillance systems | 2 | 6.36 | 4.36 | 8.36 |
| 14 | Proportion of districts having electronic vaccine and supply stock management system to monitor vaccine stock down to service delivery | Data systems and processes | 2 | 5.45 | 2.05 | 8.84 |

| Rank | Indicator | Category | Preference score | Mean feasibility-relevance score | Mean feasibility score | Mean weighted relevance score |
|------|--|----------------------------|------------------|----------------------------------|------------------------|-------------------------------|
| 15 | Proportion of districts reporting negative DTP1-DTP3 drop out | Data quality | 2 | 5.20 | 3.59 | 6.80 |
| 16 | Dropout rates between first dose (DTP1) and first dose of measles-containing vaccine (MCV1) | Immunisation coverage | 1 | 6.81 | 4.87 | 8.75 |
| 17 | Access to laboratory capacity to test for at least one bacterial vaccine-preventable disease (VPD) | VPD surveillance systems | 1 | 6.02 | 3.85 | 8.19 |
| 18 | Proportion of children with home-based immunisation records | Data systems and processes | 1 | 4.72 | 2.31 | 7.14 |
| 19 | Number of districts with DTP3 coverage in each range: <50%, 50-79%, 80-89%, 90-94, ≥95% | Immunisation coverage | 0 | 6.96 | 5.90 | 8.03 |
| 20 | Proportion of districts reporting stock availability (vaccines and supplies) at a service delivery level | Data systems and processes | 0 | 6.58 | 4.36 | 8.80 |
| 21 | Proportion of stockpile applications that demonstrate use of evidence (e.g. disease surveillance data, root cause analysis, and coverage data) to support planning/targeting of outbreak response campaigns | Use of insights | 0 | 6.32 | 4.36 | 8.28 |
| 22 | Number of districts reporting DTP drop out ranges greater than 10%, by coverage range: <50%, 50-79%, 80-89%, 90-94, ≥95% | Immunisation coverage | 0 | 6.29 | 4.62 | 7.96 |
| 23 | Proportion of districts reporting at least 90% on time during a one-year period for suspected cases for all priority vaccine-preventable diseases under nationwide surveillance, including reporting of zero cases | Data quality | 0 | 6.24 | 4.36 | 8.12 |
| 24 | Does the country collect age and/or number of vaccine doses received for all cases of vaccine-preventable disease? | VPD surveillance systems | 0 | 5.58 | 3.08 | 8.09 |
| 25 | Proportion of districts with complete and timely reporting | Data quality | -1 | 6.72 | 5.64 | 7.79 |
| 26 | Are the number of type-specific vaccine doses reported by age group (e.g. number of diphtheria cases by age group) based on recall, documentation, or both? | Data quality | -1 | 6.68 | 5.13 | 8.24 |
| 27 | Annual number of laboratory-confirmed epidemic-prone vaccine-preventable disease outbreaks | VPD surveillance systems | -1 | 6.27 | 3.85 | 8.70 |
| 28 | Number of districts with protection at birth (PAB) (against neonatal tetanus) coverage in each range: <50%, 50-79%, 80-89%, 90-94, ≥95% | Immunisation coverage | -1 | 5.83 | 4.36 | 7.29 |

| Rank | Indicator | Category | Preference score | Mean feasibility-relevance score | Mean feasibility score | Mean weighted relevance score |
|------|--|----------------------------|------------------|----------------------------------|------------------------|-------------------------------|
| 29 | Proportion of districts with on-line access to health management information systems (HMIS) | Data systems and processes | -3 | 5.68 | 2.82 | 8.54 |
| 30 | Proportion of eligible children in the disadvantaged population that are reached and vaccinated according to national schedule | Immunisation coverage | -3 | 4.31 | 1.28 | 7.33 |
| 31 | Proportion of district health management committees (or equivalent at subnational level) that review immunisation performance as part of primary health care performance at least annually | Use of insights | -4 | 4.28 | 1.79 | 6.76 |
| 32 | DTP3, MCV1, and MCV2 coverage in the 20% of districts with lowest coverage | Immunisation coverage | -5 | 6.11 | 4.62 | 7.61 |
| 33 | Number of districts reporting DTP drop out ranges greater than 10% | Immunisation coverage | -5 | 5.82 | 3.85 | 7.78 |
| 34 | Individual adverse event following immunisation (AEFI) case safety reports per million total population | Data systems and processes | -5 | 5.40 | 3.33 | 7.47 |
| 35 | Proportion of population with access to their personal immunisation records | Data systems and processes | -5 | 4.01 | 0.77 | 7.26 |
| 36 | Non-measles/non-rubella discard rate (target $\geq 2/100,000$ population) | VPD surveillance systems | -6 | 5.81 | 3.85 | 7.77 |
| 37 | Percentage points difference in coverage of DTP1, MCV1 and full immunisation coverage associated with the most important socioeconomic determinants of vaccination coverage in the country (poverty, education, ethnicity, religious affiliation) | Immunisation coverage | -6 | 4.53 | 2.05 | 7.00 |
| 38 | Does the private health sector deliver vaccines in your country and do you report it in your coverage? (Private health sector includes all organisations not owned or controlled by governments, including for-profit or not-for-profit, formal or informal, and domestic or foreign.) | Data quality | -6 | 4.28 | 3.59 | 4.97 |
| 39 | Proportion of districts with year-to-year variation of children vaccinated with DTP3 less than 15% | Data quality | -6 | 3.96 | 1.79 | 6.12 |
| 40 | Commitment tracking and accountability frameworks used at country and subnational levels | Use of insights | -6 | 3.94 | 0.77 | 7.11 |

| Rank | Indicator | Category | Preference score | Mean feasibility-relevance score | Mean feasibility score | Mean weighted relevance score |
|-------------|---|----------------------------|-------------------------|---|-------------------------------|--------------------------------------|
| 41 | Proportion of provinces/districts or other subnational units with at least one documented (with reporting form and/or line listed) individual serious AEFI case safety reports per million total population | Data systems and processes | -6 | 3.86 | 1.03 | 6.69 |

280

281 The ten highest-rated indicators included indicators from all five categories. The highest-ranked
282 indicator, “Country uses quality data on under-vaccinated to inform plans at community, subnational
283 and national levels”, received the highest mean relevance score (9.05/10). Among immunisation
284 coverage indicators, those measuring measles vaccine coverage and zero-dose vaccination coverage
285 were the most highly rated (mean relevance – MCV1 coverage: 8.29, MCV2 coverage: 8.98, zero-
286 dose coverage: 8.47). Indicators examining the establishment of systems to monitor immunisation
287 coverage (mean relevance: 9.01) and adverse events following immunisations (mean relevance:
288 8.97) were amongst the highest-rated of indicators measuring the performance of data systems for
289 immunisation. Among the fourteen indicators ranked the highest overall (i.e. top one-third of all 41
290 indicators), all except two (‘proportion of facility-level routine immunisation microplans with
291 updated catchment area maps and strategy to reach them’ and ‘linkage of home-based records with
292 civil birth registration through immunisation services’) had relevance and feasibility scores above the
293 median scores (see Figure 2).

294
295 The highest-ranked indicators were largely similar between genders and professional groups (i.e.
296 professional expertise and geographical scope of work, see Appendices 7 and 8). Zero-dose coverage
297 was the second-highest ranked indicator among experts working in more than one PIC, but ranked
298 lower by nationally-based and digital health experts (ranked 14th and 17th, respectively). Among
299 nationally-based experts, monitoring the establishment of adverse events surveillance, the use of
300 data on under-vaccinated to inform planning, and measles vaccination coverage were ranked the
301 highest among all 41 indicators.

302

303 *Factors influencing preferences for indicators*

304 Experts highlighted two major reasons for preferencing indicators: 1) usefulness for decision-making
305 and planning, and 2) ease of data collection, reporting and interpretation.

306

307 1. Usefulness for decision-making and planning

308 During the discussions, experts repeatedly expressed that they selected indicators that inform policy
309 considerations to strengthen immunisation programs and make programmatic decisions. Experts
310 discussed how they used certain insights in decision-making to develop microplans and target
311 resources, stating that their preferred indicators helped to devise strategies to reach unvaccinated
312 children and plan for delivery including managing logistics and supply chains. Experts wanted data
313 that led to action and helped inform strategies to improve immunisation:

314 *“I mean, it's talking about using data for action, right? So that all the data that we are*
315 *collecting, I think countries are interested in, how does it contribute to policy? How does it*
316 *contribute to program improvement? How does it contribute to reaching children and*
317 *communities with vaccines? So that's very interesting about it. And I think that this, that shows*
318 *you that all stakeholders are interested in the data not just being collected, but actually being*
319 *used to inform planning.” (Immunisation expert working across multiple PICs)*

320

321 Experts frequently discussed that their indicator preferences were driven by a desire to know where
322 performance was suboptimal as this helped to keep the issue on the agenda and ensure resources
323 are allocated to improve performance. For example, two experts discussed how in their respective
324 countries, coverage of vaccines doses in multi-dose schedules (i.e. DTP and measles vaccines) was
325 high and stable in the first year of life, but there was high dropout and coverage of doses given later
326 in life was lower. Having insights on the coverage of these later doses was valued more as it helped
327 to identify where problems were specifically occurring (e.g. which provinces) and make decisions
328 about where to target resources, as well as advocate for additional resources from higher-level
329 decision-makers and politicians. Other experts discussed that knowing coverage rates for the first
330 dose of measles (or valuing both equally) was their preference because their primary concern was
331 preventing measles outbreaks. In a different example, an expert cited how the proportions of births
332 registered in their country was found to be low and that this insight helped to drive actions to

333 improve birth registrations. This expert valued continued monitoring of that indicator to ensure that
334 there was continued progress, and prompt action in case performance worsened.

335

336 Experts highlighted additional areas where challenges are known that should be monitored as they
337 were integral to immunisation system performance. Limited health worker capacity was frequently
338 noted, with experts discussing how shortages in nursing staff hindered the ability to administer
339 vaccinations. High turnover resulted in the program being implemented by inexperienced staff who
340 lack competencies in using insights effectively to identify unvaccinated children. Vaccine shortages
341 and stockouts were also noted to disrupted vaccination efforts, with monitoring necessary to
342 determine the origin of the problem (e.g. whether the stockout was due to poor stock management
343 at the facility level or a national issue due to lack of payment to the manufacturer) and therefore the
344 solution.

345

346 Experts discussed their preference for indicators that measure the performance of areas where
347 there have been recent efforts to improve systems, particularly establishing robust surveillance
348 systems for adverse events following immunisations and digital individualised immunisation
349 information systems. Experts explained that the need for these systems during the COVID-19
350 pandemic had attracted substantial investment and political will to establish them, so these were
351 priority areas where countries wished to demonstrate progress and achieve targets. Experts also
352 explained that establishment of these systems required multiple elements of the health system to
353 come together, so achieving these goals demonstrated health system strengthening.

354

355 2. Ease of data collection, reporting and interpretation

356 Experts expressed a strong preference for indicators for which data are relatively easier to collect
357 and analyse, and identified difficulties in collecting, reporting and interpreting data as reasons not to
358 select indicators. Factors that affected the feasibility of data collection and reporting included

359 whether the data were currently captured by existing health information systems, difficulties in
360 defining subpopulation groups, having sufficient resources for data collection and reporting, lacking
361 data systems that enable easier reporting, and complexity of synthesis. Workforce constraints were
362 frequently cited as a barrier, with experts noting the need to be pragmatic about what insights can
363 be generated as the resources required were either absent or incommensurate with the benefits of
364 having those insights. This was especially highlighted in discussions regarding reporting coverage
365 data by geographical and socioeconomic groups, as collecting and reporting data at more granular
366 levels was considered particularly resource-intensive:

367 *“This may be a distinction that needs to be made between whether or not, the indicator is*
368 *important, and like, how difficult it would be to get the information, accurate information to,*
369 *to report against that indicator. I think in my case, I probably just wanted to remove the*
370 *indicators that I felt, which is beyond the scope of the capacity, the organisation to be able to*
371 *go out and collect rather than necessarily being important. So I think it's like the*
372 *socioeconomic determinants, vaccination coverage might be really providing very valuable*
373 *information. But to get to that information is just very complicated and challenging.” (Health*
374 *information specialist working in a single PIC)*

375

376 *“Regarding managers and people dealing with data, we are very few. For example, in [PIC*
377 *name omitted], for [hundreds of thousands] people, I am alone to manage all that. And not*
378 *only the vaccines, but also other ID [infectious disease] programs.” (Immunisation manager*
379 *working in a single PIC)*

380

381 Experts also voiced a preference for indicators that were simple and straightforward to interpret.
382 Experts objected to indicators that were poorly defined, lengthy, had complex wording, had multiple
383 layers or could be interpreted in multiple ways (such as “Percentage points difference in coverage of
384 DTP1, MCV1 and full immunisation coverage associated with the most important socioeconomic

385 determinants of vaccination coverage in the country”). Complex, wordy indicators were considered
386 to be confusing, ambiguous and lacking clarity in what they were measuring, which presented
387 challenges both in using insights but also in determining how to collect the data. Terms such as
388 “disadvantaged population”, for example, were not clearly defined and interpreted differently by
389 experts, with some stating that everyone in their country had access to immunisations so there was
390 no “disadvantage” as such.

391

392 *Context-specific factors influencing indicator preferences*

393 Factors that explained differences in experts’ preferences for indicators fell into four themes: A)
394 differences in health priorities, B) differences in health system structures, C) priorities and
395 experiences of different immunisation actors, and D) challenges due to small and mobile
396 populations.

397

398 A. Differences in health priorities

399 Experts differed in how they rated certain indicators as they either did not align with what they
400 believed were urgent priorities for immunisation or because they did not think it would help them
401 improve immunisation coverage. One such indicator was the number of zero-dose children (defined
402 as those lacking a dose of DTP-containing vaccine), with several experts considering it important to
403 report data on this indicator to ensure no child is unvaccinated. However, perspectives on the extent
404 of zero-dose vaccination as a public health problem in specific PICs varied, and was believed to be
405 more important in countries with lower coverage of routine childhood vaccinations and less so for
406 those with high coverage. Some felt that there were very small numbers of unvaccinated children in
407 their country so the relative benefit of having this indicator and spending resources on finding and
408 vaccinating these children was small. Others felt that zero-dose children were more common than
409 statistics indicated, with coverage rates believed to be inaccurately inflated due to issues with
410 population denominators. One expert suggested that simply knowing there were unvaccinated

411 children was insufficient, and that the reasons why they were un- or under-vaccinated was just as
412 important. Some also expressed concern about focusing on coverage of one type of vaccine, when
413 full vaccination was the goal.

414

415 Another indicator where preferences varied was for the proportion of live births registered. Some
416 experts viewed this as a priority for improvement as it influenced the calculations for all coverage
417 and other health indicators, while others did not see how this insight could help improve
418 immunisation performance and believed other sources of birth data could be used for follow-up of
419 children due for vaccination. Similarly, indicators measuring VPD surveillance capacity were viewed
420 by some experts to be important for VPD detection and outbreak management, but viewed by
421 others as beyond the scope of the immunisation program and therefore irrelevant for monitoring
422 immunisation performance.

423

424 B. Differences in health system structures

425 Experts discussed how differences in health system structures and maturity affected preferences for
426 indicators, particularly those measuring the performance of data systems. Some noted that French-
427 overseas collective PICs and US-Affiliated Pacific Islands have additional resources enabling them to
428 have more advanced systems with digital capabilities. Other countries are in earlier stages of
429 establishing new systems for immunisation data and only just starting to digitise information
430 systems, so measuring data quality or enabling linkage of different data systems are secondary to
431 ensuring that effective systems to record data are established. Some experts discussed how
432 capabilities vary even within countries, with the use of digital technologies to record data limited by
433 infrastructural issues like electricity and internet connectivity.

434

435 Another example where health system factors affected indicator preferences was for indicators
436 measuring VPD surveillance systems. Experts agreed that laboratory capacity to detect VPDs is a gap

437 across the Pacific Islands, but differed on how important they considered this to be. Some thought it
438 is a major problem for detecting and responding to outbreaks, often receiving the diagnosis for a
439 suspected measles case several weeks after the first case. Others acknowledged that increasing
440 laboratory capacity in some countries, especially the smallest PICs, was unlikely to be practical or
441 cost-effective, thus indicators measuring laboratory capacity were irrelevant in those contexts.

442

443 C. Priorities and experiences of different immunisation actors

444 Experts discussed differing preferences based on their roles, experiences and sphere of influence.
445 Some experts, including those from global development organisations, noted the tension created by
446 the requirements for reporting imposed by external actors, noting there were often discrepancies in
447 what was interesting to donors and funders, but not necessarily feasible and meaningful to collect
448 from countries' perspectives. Experts expressed frustration that development partners did not
449 always agree on the number of indicators or the types of indicators that are important, creating
450 additional work and confusion.

451

452 Among experts working in a single PIC, preferences for indicators were affected by their scope of
453 work and level of responsibility. This was particularly discussed in relation to the indicator about the
454 completeness of birth registration data – while some experts considered this important to be able to
455 interpret immunisation and other health statistics, others considered this beyond their scope of
456 work in immunisation and not wanting to be accountable for a performance measure they could not
457 influence.

458

459 D. Challenges due to small and highly mobile populations

460 Experts repeatedly cited the small population sizes in PICs as being the reason why some indicators
461 were irrelevant or difficult to interpret. With small population sizes and therefore a smaller
462 workforce with a few people doing the same work of multiple people in larger countries, certain

463 governance structures used in larger countries were considered redundant or unnecessary. For
464 example, experts noted that subnational-level governance committees were impractical, and in fact
465 even at the national level there were insufficient skilled workforce to establish national
466 immunisation technical advisory groups in each PIC. Small population sizes also made interpretation
467 of some statistics challenging, with experts noting that denominators of “per million” (e.g. AEFI
468 reports per million) were especially troublesome given that PICs have populations much less than
469 one million people. This was particularly the case for rare events, where a single additional serious
470 AEFI case can mean a large rise in rates.

471

472 Experts especially cited difficulties in generating data by granular geographical areas as problematic.
473 None of the experts supported reporting statistics by district, citing its irrelevance to decision-
474 making in their respective countries, and difficulties in collecting, reporting and interpreting data at
475 this level. They explained that scenarios such as a child being born in one district (where their birth is
476 registered), living in a second, and going to school in a third were common, with vaccinations
477 administered being captured in an area other than the child’s birth district. Thus, low coverage rates,
478 rates over 100% and negative dropout rates at subnational levels reflect movements rather than
479 poor performance or inaccuracies. Some experts stated that in their context, other subnational
480 denominations, like province, island or health facility catchment area, were better aligned with the
481 way health service delivery was organised and therefore more useful for planning services and
482 identifying pockets of under-vaccinated populations. For higher level decision-making, experts
483 preferred to routinely monitor insights at the national level, while conducting deep dives into
484 specific areas if a problem is detected or suspected.

485

486 *Characteristics of a set of indicators*

487 As the original objective of this study was to create a single set of indicators suitable for PICs, experts
488 were asked about their preferences were for characteristics of a set of indicators (see Box 1). Experts

489 unanimously preferred to have smaller sets of indicators, citing the burden of data collection and
490 reporting in a small island nation context. Experts considered between ten and 15 indicators to be
491 sufficient and manageable for national immunisation performance monitoring, with more
492 considered tedious and challenging to report. Less data were also considered to be more influential,
493 with only limited insights being used to demonstrate a need or performance improvements, or to
494 make decisions. Experts said fewer insights to be more likely to be reviewed and used than long lists
495 of insights, and therefore lead to concrete actions. Some experts stated that having too many
496 insights could inadvertently lead to an aversion to using them. Experts also preferred including
497 indicators that encompassed a broad range of outcomes rather than having indicators that provided
498 depth of information on a specific outcome. They viewed in-depth investigations as being a second
499 step and more appropriate if suboptimal performance was detected at the national level,
500 particularly given the small populations in PICs and practical difficulties of obtaining insights at
501 subnational levels.

502 **Box 1: Desirable characteristics of a set of indicators monitoring national immunisation**
503 **performance in Pacific Island Countries and Areas as identified by experts in this study**

Indicator characteristics:

- Relevance to decision making: informs program planning, demonstrates progress (or lack thereof) in an area of focus or importance, identifies problems, informs a public health action
- Relates to a priority area
- Feasible to collect, analyse, and report within the resources and health and information technology infrastructure available
- Simply worded and easy to understand and interpret
- Meaningful in the context where it is being used
- Reported data are of high quality (i.e. accurate, reliable, trustworthy)

Characteristics of sets of indicators:

- Provides a broad (but not necessarily in-depth) overview of immunisation performance
- Fewer indicators – between 10 to 15 indicators (up to 20, depending on the context)
- Included indicators are not redundant

504

505 Discussion

506 Our study found substantial variation in which indicators experts believed were most important for
507 immunisation performance in the Pacific Island region. This was contrary to our initial hypothesis
508 that a common set of indicators could be formed for this geographical region with many shared
509 constraints. Despite this, we found that experts had similar reasons for selecting indicators, with
510 differences in indicator preferences reflecting differing immunisation goals and health system
511 constraints across countries. We found relevance to decision-making correlated with preferences for
512 indicators, consistent with findings from other studies where experts have selected indicators to
513 measure healthcare performance.^{8,25–28} Experts in our study considered indicators to be more
514 relevant if they monitored areas of priority and if they led to public health action. Feasibility was also
515 an important consideration that experts cited as a factor to screen indicators in or out. The burden
516 of data collection and reporting is well-documented in resource-constrained countries.^{2,7,29,30} For
517 Pacific Island countries with small, dispersed populations and a constrained workforce hampered
518 further by skilled personnel emigration,^{31,32} the opportunity costs of collecting and reporting
519 immunisation data are even higher.

520

521 There were certain indicators, or areas of measurement, that experts broadly agreed were relevant
522 and important to measure across the Pacific. Indicators for measles vaccination coverage, for
523 example, were unanimously agreed to be the most important coverage indicator, influenced by the
524 recent measles epidemic in the Pacific region^{33,34} and concerns about outbreaks following
525 disruptions to routine immunisation during the COVID-19 pandemic.^{35–37} There was also agreement
526 that some indicators were not useful to decision-makers, such as coverage indicators at specific
527 subnational divisions.

528

529 Experts differed in their preferences for indicators when the insight lacked utility in a specific
530 context, and were not always in favour of some indicators adopted by the global immunisation

531 community to strengthen immunisation. For example, zero-dose vaccination coverage has been
532 promoted as a means to improve equity and universal health coverage,^{38,39} but not all experts
533 perceived reaching unvaccinated children to be a challenge in their context and therefore less
534 valuable in their setting. While zero-dose coverage is operationally defined as those lacking a first
535 dose of DTP vaccine for simplicity, questions have been raised about the best way to define “zero-
536 dose” both by experts in our study and more broadly.⁴⁰ Similarly, experts agreed that preventing
537 measles and strong surveillance capabilities were a high priority, but cited challenges with increasing
538 laboratory capacity for testing that rendered indicators like the non-measles discard rate less useful.
539 The lack of feasibility of increasing laboratory capacity to global standards has been a challenge to
540 verification of measles elimination in PICs,⁴¹ highlighting how targets reasonable for larger countries
541 may be unattainable, and possibly unnecessary, for PICs.

542

543 Standardising data reporting at the global level has the benefit of being able to compare
544 performance across countries’ and time, encouraging visibility and accountability to achieve
545 progress towards immunisation goals.⁴² This is particularly true for targets that are well-established
546 markers of immunisation performance like DTP vaccine and MCV coverage.⁴³ Standardising
547 immunisation performance indicators globally also has the advantage of providing a common
548 framework, making monitoring and evaluation mainstream practice, and drawing attention to issues
549 with data quality.⁴² However, a one-size-fits-all approach to immunisation performance monitoring
550 wastes finite health resources, and may conversely have the adverse impact of discouraging the use
551 of insights especially at subnational levels.⁴⁴ Frustration about reporting data to external
552 organisations when the insights were not useful to decision-makers was unanimous among our
553 experts. Externally-imposed demands for data limits resources to measure indicators that are more
554 informative to decision-makers, a problem that has been reported even among large healthcare
555 organisations in high-resource settings.⁵

556

557 While the Immunization Agenda 2030 Monitoring and Evaluation Framework (which guides global
558 immunisation monitoring) allows for some flexibility in selecting indicators at the national level, in
559 practice countries are required to submit data on a vast number of indicators. To minimise the
560 burden of data collection, one approach to global immunisation performance measurement could
561 be to mandate reporting on a minimum set of core indicators, supplemented by optional indicators
562 that countries can select to suit their country context. Core indicators should have clear evidence
563 demonstrating that their achievement leads to public health benefits like improvements in
564 vaccination coverage, reductions in disease morbidity and mortality, or the advancement of
565 universal health care. An alternative approach is to mandate measuring performance in a specific
566 area (e.g. vaccination coverage or AEFI surveillance) without mandating reporting of a specific
567 indicator.

568

569 *Strengths and limitations of the study*

570 We used an expert elicitation methodology for our study as it allowed us to use a systematic
571 approach to identifying indicator preferences while quantifying the degree of uncertainty in
572 indicator ratings, acknowledging the differing roles and level of experience of participants. The
573 qualitative component allowed us to identify reasons to explain the lack of consensus on which
574 indicators are preferred, and helped to identify a common set of criteria that experts use to
575 determine which indicators are best used to measure immunisation performance.

576

577 We limited the criteria used to rate indicators to feasibility and relevance to decision-making, which
578 we considered to be the most important criteria to identify context-specific indicators and are most
579 frequently used in similar studies.^{45,46} Other studies include additional criteria, such as validity,
580 reliability and significance/importance.^{8,26–28,46} We did not include attributes of the indicator itself as
581 criteria as we identified indicators in existing monitoring and evaluation resources, and considered
582 that they had been through an appraisal process. Preferences for indicators are complex and may be

583 affected by a variety of factors that may not be possible to capture through specific criteria. One of
584 the strengths of our method is that we asked experts, all things considered, which indicators would
585 they prefer. This aimed to account for those factors which we did not, or could not, measure, while
586 being pragmatic about the number of criteria we asked experts to rate on. While others indicator
587 appraisal tools, like the Appraisal of Indicators through Research and Evaluation instrument⁴⁷ and
588 the Quality Indicator Critical Appraisal Tool⁴⁵, include several attributes to assess indicators, they
589 would likely be very time-consuming when considering a large number of indicators.

590

591 One of the limitations of our study was that we did not include indicators measuring all aspects of
592 immunisation programs. This was a pragmatic consideration, as we acknowledged that experts were
593 time-poor and unlikely to dedicate several hours to rate upwards of 100 indicators for the purpose
594 of research. Even with fewer indicators, some experts noted that it was time-consuming to think
595 through indicators using multiple criteria. Conducting the elicitation remotely possibly added to this
596 challenge, especially as Pacific culture strongly values interpersonal and community connections⁴⁸
597 which were more challenging to establish through online meetings, whereas a face-to-face
598 elicitation may have provided greater opportunity build connections and clarify questions. If
599 replicating this exercise for programmatic purposes and if resources permit, a half-day or full-day in-
600 person workshop to work through a larger set of immunisation indicators would be ideal, as has
601 been done in the past for other purposes.^{25,49}

602

603 Our study included 13 purposively-sampled experts, which is arguably small to represent the
604 diversity of countries, priorities and roles across different PICs, and may not be representative of all
605 PICs. We made a pragmatic decision not to include experts from Papua New Guinea in this study as
606 we considered the economic and political situation there to be vastly different to that of other PICs,
607 noting our initial aim was to develop a single list of immunisation performance indicators for all PICs.
608 However, there are many shared sociocultural determinants and operational challenges to

609 delivering immunisation programs, and some of our experts referred to Papua New Guinea in
610 discussions. Additionally, our method of identifying potential experts and recruitment via email and
611 through professional contacts may have introduced bias into the study. Recruitment occurred while
612 the COVID-19 pandemic response was ongoing, so some experts with experience highly relevant to
613 this study may not have had capacity to participate in the study. Nevertheless, included experts
614 collectively had several years' worth of experience, with four individually having more than ten
615 years' experience working in PICs. Experts also generally agreed that the highest ranked indicators
616 reflected the most important immunisation priorities in their specific settings and across the Pacific,
617 and the themes that arose in discussions were recurring, providing a degree of confidence in the
618 validity of our results. We also acknowledge that our prior experiences, assumptions and beliefs may
619 have influenced the research process, particularly the facilitation and analysis of discussions with
620 experts. We attempted to minimise bias by providing all experts with an opportunity to review their
621 ratings and make changes, and having two authors independently review discussion transcripts to
622 identify and categorise themes which were agreed to by all authors.

623

624 **Conclusions**

625 Our study highlights the value of selecting performance indicators to monitor immunisation
626 programs that are context-specific and aligned with the priorities, goals and capabilities of the
627 country. Immunisation and health systems in the Pacific Islands and the challenges to immunisation
628 programs are vastly different to those in other countries, and our study shows that differences even
629 within the Pacific region mean that it would be inappropriate to have a single set of indicators
630 measuring immunisation performance for all PICs. Rather, performance indicators should be
631 country-specific, with countries having the flexibility to set short, medium and long term goals for
632 their own immunisation programs, informed by evidence and their specific contexts. Further
633 research is necessary to determine if this contextualised approach to monitoring and evaluation
634 leads to tangible improvements in immunisation performance.

636 **Acknowledgements**

637 We would like to thank all experts who participated in this study for the time and contributions. We
638 would also like to thank Dr Md. Shafiqul Hossain, Dr Kerrie Wiley and Ms Nicole Rendell for testing
639 and piloting the elicitation instrument.

640

641 **Author contributions**

642 All authors meet the ICMJE authorship criteria. CP, MS, GS and AA conceived the study idea and
643 jointly developed the study methodology with HM. CP collected the data. CP and AD completed the
644 analysis with input from MS, GS and DC. CP synthesized the findings and drafted the first draft of the
645 manuscript. IT provided input into the Pacific context and expert advice. All authors contributed to
646 interpreting study findings reviewed and edited, and agreed on the final version. MS supervised the
647 conduct of the study.

648

649 **Funding statement**

650 CP is supported by an Australian Government Research Training Program (RTP) Scholarship. MS was
651 funded by a research fellowship from the Westpac Scholars Trust (2019-2023). The funders had no
652 role in the design, conduct or writing of this study.

653

654 **Declarations of interest**

655 We declare no competing interests.

656 References

- 657 1. Immunization Agenda. Immunization Agenda 2030: A global strategy to leave no one behind
658 [Internet]. 2020 [cited 27 Feb 2024]. Available from:
659 <https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030>
- 660 2. Scobie HM, Edelstein M, Nicol E, Morice A, Rahimi N, MacDonald NE, et al. Improving the
661 quality and use of immunization and surveillance data: Summary report of the Working Group
662 of the Strategic Advisory Group of Experts on Immunization. *Vaccine*. 2020;38(46):7183–97.
- 663 3. Patel C, Rendell N, Sargent GM, Ali A, Morgan C, Fields R, et al. Measuring National
664 Immunization System Performance: A Systematic Assessment of Available Resources. *Glob
665 Health Sci Pract*. 202;11(3):e220055.
- 666 4. Cassel CK, Conway PH, Delbanco SF, Jha AK, Saunders RS, Lee TH. Getting More Performance
667 from Performance Measurement. *N Engl J Med*. 2014;371(23):2145–7.
- 668 5. Meyer GS, Nelson EC, Pryor DB, James B, Swensen SJ, Kaplan GS, et al. More quality measures
669 versus measuring what matters: a call for balance and parsimony. *BMJ Qual Saf*.
670 2012;21(11):964–8.
- 671 6. Osterman AL, Shearer JC, Salisbury NA. A realist systematic review of evidence from low- and
672 middle-income countries of interventions to improve immunization data use. *BMC Health Serv
673 Res*. 2021;21(1):672.
- 674 7. Wetherill O, Lee C won, Dietz V. Root Causes of Poor Immunisation Data Quality and Proven
675 Interventions: A Systematic Literature Review. *Annals of Infectious Disease and Epidemiology*.
676 2017;2(1):7.
- 677 8. Carinci F, Van Gool K, Mainz J, Veillard J, Pichora EC, Januel JM, et al. Towards actionable
678 international comparisons of health system performance: expert revision of the OECD
679 framework and quality indicators. *International Journal for Quality in Health Care*.
680 2015;27(2):137-146.
- 681 9. MacDonald N, Mohsni E, Al-Mazrou Y, Kim Andrus J, Arora N, Elden S, et al. Global vaccine
682 action plan lessons learned I: Recommendations for the next decade. *Vaccine*.
683 2020;38(33):5364–71.
- 684 10. World Health Organization Western Pacific Region. Pacific Island Countries and Areas – WHO
685 Cooperation Strategy 2018–2022. 2017 [cited 5 Dec 2023]. Available from:
686 [https://www.theprif.org/sites/default/files/documents/WHO%20Cooperation%20Strategy%20
687 for%20the%20Pacific%202018-2022.pdf](https://www.theprif.org/sites/default/files/documents/WHO%20Cooperation%20Strategy%20for%20the%20Pacific%202018-2022.pdf)
- 688 11. Tyson S, Clements J. Strengthening Development Partner Support to Immunisation Programs in
689 the Pacific. 2016;81. Available from:
690 [https://www.dfat.gov.au/sites/default/files/strengthening-dev-partner-support-to-
691 immunisations-programs-pacific-strat-review.pdf](https://www.dfat.gov.au/sites/default/files/strengthening-dev-partner-support-to-immunisations-programs-pacific-strat-review.pdf)
- 692 12. World Health Organization Regional Office of the Western Pacific. Health information systems
693 in the Pacific at a glance 2016. [cited 8 Mar 2024]. Available from:
694 [https://apps.who.int/iris/bitstream/handle/10665/259091/9789290618195-
695 eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/259091/9789290618195-eng.pdf?sequence=1)

- 696 13. Matheson D, Park K, Soakai TS. Pacific island health inequities forecast to grow unless profound
697 changes are made to health systems in the region. *Aust Health Review*. 2017;41(5):590.
- 698 14. World Health Organization Western Pacific Region. The first 20 years of the journey towards
699 the vision of Healthy Islands in the Pacific. 2015 [cited 8 Mar 2024]. Available from:
700 [https://apps.who.int/iris/bitstream/handle/10665/208201/9789290617150_eng.pdf?sequenc](https://apps.who.int/iris/bitstream/handle/10665/208201/9789290617150_eng.pdf?sequence=1&isAllowed=y)
701 [e=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/208201/9789290617150_eng.pdf?sequence=1&isAllowed=y)
- 702 15. Sheel M, Tippins A, Glass K, Kirk M, Lau CL. Electronic immunization registers – A tool for
703 mitigating outbreaks of vaccine-preventable diseases in the Pacific. *Vaccine*.
704 2020;38(28):4395–8.
- 705 16. Advancing health information and digital transformation in the health sector. In 2023 [cited 27
706 Feb 2024]. Available from: [https://cdn.who.int/media/docs/default-source/wpro---](https://cdn.who.int/media/docs/default-source/wpro---documents/dps/phmm-phoh-documents/15th-phmm/advancing-health-information-and-digital-transformation-phmm-paper.pdf?sfvrsn=907f2b43_1)
707 [documents/dps/phmm-phoh-documents/15th-phmm/advancing-health-information-and-](https://cdn.who.int/media/docs/default-source/wpro---documents/dps/phmm-phoh-documents/15th-phmm/advancing-health-information-and-digital-transformation-phmm-paper.pdf?sfvrsn=907f2b43_1)
708 [digital-transformation-phmm-paper.pdf?sfvrsn=907f2b43_1](https://cdn.who.int/media/docs/default-source/wpro---documents/dps/phmm-phoh-documents/15th-phmm/advancing-health-information-and-digital-transformation-phmm-paper.pdf?sfvrsn=907f2b43_1)
- 709 17. World Health Organization. WHO’s work in the Pacific in 2021. 2022 [cited 27 Feb 2024].
710 Available from: [https://www.who.int/fiji/news/feature-stories/who-s-work-in-the-pacific-in-](https://www.who.int/fiji/news/feature-stories/who-s-work-in-the-pacific-in-2021)
711 [2021](https://www.who.int/fiji/news/feature-stories/who-s-work-in-the-pacific-in-2021)
- 712 18. UNICEF Pacific Islands. Childhood immunization begins recovery after COVID-19 backslide.
713 2023 [cited 13 Feb 2024]. Available from: [https://www.unicef.org/pacificislands/press-](https://www.unicef.org/pacificislands/press-releases/childhood-immunization-begins-recovery-after-covid-19-backslide)
714 [releases/childhood-immunization-begins-recovery-after-covid-19-backslide](https://www.unicef.org/pacificislands/press-releases/childhood-immunization-begins-recovery-after-covid-19-backslide)
- 715 19. The World Bank. World Development Indicators | DataBank [Internet]. 2024 [cited 27 Feb
716 2024]. Available from: <https://databank.worldbank.org/source/world-development-indicators>
- 717 20. Kawakyu N, Coe M, Wagenaar BH, Sherr K, Gimbel S. Refining the Performance of Routine
718 Information System Management (PRISM) framework for data use at the local level: An
719 integrative review. Nicol E, editor. *PLoS ONE*. 2023;18(6):e0287635.
- 720 21. Hemming V, Burgman MA, Hanea AM, McBride MF, Wintle BC. A practical guide to structured
721 expert elicitation using the IDEA protocol. Anderson B, editor. *Methods Ecol Evol*.
722 2018;9(1):169–80.
- 723 22. Knol AB, Slottje P. The use of expert elicitation in environmental health impact assessment: a
724 seven step procedure. 2010;9:19.
- 725 23. Grigore B, Peters J, Hyde C, Stein K. A comparison of two methods for expert elicitation in
726 health technology assessments. *BMC Med Res Methodol*. 2016;16(1):85.
- 727 24. Ward DJ, Furber C, Tierney S, Swallow V. Using Framework Analysis in nursing research: a
728 worked example. *J Adv Nurs*. 2013;69(11):2423–31.
- 729 25. Grube MM, Scheidt-Nave C, Gaertner B, Lüdtke D, Bosnjak M, Heinrich S, et al. The selection
730 and definition of indicators in public health monitoring for the 65+ age group in Germany. *J*
731 *Health Monit*. 2019;4(2):86–101.
- 732 26. Ahuja S, Gronholm PC, Shidhaye R, Jordans M, Thornicroft G. Development of mental health
733 indicators at the district level in Madhya Pradesh, India: mixed methods study. *BMC Health*
734 *Serv Res*. 2018;18(1):867.

- 735 27. Jordans MJD, Chisholm D, Semrau M, Upadhaya N, Abdulmalik J, Ahuja S, et al. Indicators for
736 routine monitoring of effective mental healthcare coverage in low- and middle-income
737 settings: a Delphi study. *Health Policy Plan.* 2016;31(8):1100–6.
- 738 28. Rich R, D’Hont T, Murphy KE, Veillard J, Chatwood S. Selecting contextually appropriate
739 performance indicators in a circumpolar context: a modified Delphi approach. *BMC Health Serv
740 Res.* 2021;21(1):530.
- 741 29. Siyam A, Ir P, York D, Antwi J, Amponsah F, Rambique O, et al. The burden of recording and
742 reporting health data in primary health care facilities in five low- and lower-middle income
743 countries. *BMC Health Serv Res.* 2021;21(S1):691.
- 744 30. Mboera LEG, Rumisha SF, Mbata D, Mremi IR, Lyimo EP, Joachim C. Data utilisation and factors
745 influencing the performance of the health management information system in Tanzania. *BMC
746 Health Serv Res.* 2021;21(1):498.
- 747 31. Yamamoto TS, Sunguya BF, Shiao LW, Amiya RM, Saw YM, Jimba M. Migration of Health
748 Workers in the Pacific Islands: A Bottleneck to Health Development. *Asia Pac J Public Health.*
749 2012;24(4):697–709.
- 750 32. Martin E, Snowdon W, Moadsiri A, Volavola S, Bell C. Pacific Healthy Islands Vision: success
751 factors and challenges faced by health promotion programs. *Health Promotion International.*
752 2023;38(3):daac002.
- 753 33. Craig AT, Heywood AE, Worth H. Measles epidemic in Samoa and other Pacific islands. *The
754 Lancet Infectious Diseases.* 2020;20(3):273–5.
- 755 34. Kaspar A, Pifeleti S, Whitfield BC. The measles emergency is over, but the crisis continues – a
756 call to action for the Pacific Islands. *Journal of Global Health.* 2020;10(2):020301.
- 757 35. Durrheim DN, Baker MG, Capeding MR, Goh KT, Lee D, Papania M, et al. Accelerating measles
758 elimination in the Western Pacific Region during the calm between the storms. *The Lancet
759 Regional Health - Western Pacific.* 2022;23:100495.
- 760 36. Durrheim DN, Andrus JK, Tabassum S, Bashour H, Githanga D, Pfaff G. A dangerous measles
761 future looms beyond the COVID-19 pandemic. *Nat Med.* 2021;27(3):360–1.
- 762 37. Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha SV, Wallace AS. Routine Vaccination
763 Coverage — Worldwide, 2021. [https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7144a2-
764 H.pdf](https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7144a2-H.pdf). 2022;71(44):5.
- 765 38. Hogan D, Gupta A. Why Reaching Zero-Dose Children Holds the Key to Achieving the
766 Sustainable Development Goals. *Vaccines.* 2023;11(4):781.
- 767 39. de Oliveira Cata-Preta B, Melo Santos T, Mengistu T, R. Hogan D, J.D. Barros A, Victora CG.
768 Zero-dose children and the immunisation cascade: Understanding immunisation pathways in
769 low and middle-income countries. *Vaccine.* 2021;S0264410X21002632.
- 770 40. Equity Reference Group for Immunization (ERG). A focus on ‘zero dose’ children: Key issues for
771 consideration. 2020 [cited 16 Sep 2023]. Available from: [https://irp.cdn-
772 website.com/44236788/files/uploaded/ERG%20Discussion%20Paper%209%20Zero%20Dose%
773 20FINAL.pdf](https://irp.cdn-website.com/44236788/files/uploaded/ERG%20Discussion%20Paper%209%20Zero%20Dose%20FINAL.pdf)

- 774 41. World Health Organization Western Pacific Region. Tenth Annual Meeting of the Regional
775 Verification Commission for Measles and Rubella Elimination in the Western Pacific - 12 to 16
776 September 2022. Manila, Philippines: World Health Organization Regional Office for the
777 Western Pacific; 2022 [cited 5 Mar 2024]. Available from:
778 [https://iris.who.int/bitstream/handle/10665/365590/RS-2022-GE-14-PHL-](https://iris.who.int/bitstream/handle/10665/365590/RS-2022-GE-14-PHL-eng.pdf?sequence=1&isAllowed=y)
779 [eng.pdf?sequence=1&isAllowed=y](https://iris.who.int/bitstream/handle/10665/365590/RS-2022-GE-14-PHL-eng.pdf?sequence=1&isAllowed=y)
- 780 42. Cherian T, Hwang A, Mantel C, Veira C, Malvolti S, MacDonald N, et al. Global Vaccine Action
781 Plan lessons learned III: Monitoring and evaluation/accountability framework. *Vaccine*.
782 2020;38(33):5379–83.
- 783 43. Lindstrand A, Cherian T, Chang-Blanc D, Feikin D, O’Brien KL. The World of Immunization:
784 Achievements, Challenges, and Strategic Vision for the Next Decade. *The Journal of Infectious*
785 *Diseases*. 2021;224(Supplement_4):S452–67.
- 786 44. Noor AM. Country ownership in global health. Robinson J, editor. *PLOS Glob Public Health*.
787 2022;2(2):e0000113.
- 788 45. Jones P, Shepherd M, Wells S, Le Fevre J, Ameratunga S. Review article: What makes a good
789 healthcare quality indicator? A systematic review and validation study. *Emergency Medicine*
790 *Australasia*. 2014;26(2):113–24.
- 791 46. Heenan MA, Randall GE, Evans JM. Selecting Performance Indicators and Targets in Health
792 Care: An International Scoping Review and Standardized Process Framework. *Risk Manag*
793 *Healthc Policy*. 2022;15:747–64.
- 794 47. de Koning J, Burgers J, Klazinga N. Appraisal of Indicators through Research and Evaluation
795 (AIRE). 2007.
- 796 48. McElfish PA, Yeary K, Sinclair KA, Steelman S, Esquivel MK, Aitaoto N, et al. Best Practices for
797 Community-Engaged Research with Pacific Islander Communities in the US and USAPI: A
798 Scoping Review. *Journal of Health Care for the Poor and Underserved*. 2019;30(4):1302–30.
- 799 49. Meyer D, Bishai D, Ravi SJ, Rashid H, Mahmood SS, Toner E, et al. A checklist to improve health
800 system resilience to infectious disease outbreaks and natural hazards. *BMJ Glob Health*.
801 2020;5(8):e002429.
- 802




Figure 1




Figure 2A




Figure 2B






Figure 2C



$r=0.6663$

Figure 2D



Note: Dashed lines show median values

$r=0.552$

Figure 3